Corvus CEO thinks his next blockbuster is an ITK inhibitor
It’s like “Rituxan all over again,” said CEO Richard Miller who believes Corvus’ lead candidate could make an impact in both cancer and...
It’s like “Rituxan all over again,” said CEO Richard Miller who believes Corvus’ lead candidate could make an impact in both cancer and autoimmune diseases.